Search - tctmd.com

Displaying 121 - 140 of 305

Sort: Relevancy | Date

Presentation ACC 2019

Primary Results From the Evolut Low Risk Trial

Presenter: Michael J. Reardon

March 17, 2019

Presentation ACC 2019

PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis

Presenter: Martin B. Leon

March 17, 2019

Presentation CRT 2019

Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis

Presenter: Ron Waksman

March 05, 2019

Presentation

Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Low Risk

February 06, 2019

Bioprosthetic structural valve degeneration

Presentation CDM 2018

TAVR is Here to Stay: What About TAVR in Low-Risk Patients?

Presenter: Joseph P. Carrozza

October 12, 2018

Presentation TCT 2018

OBSERVANT: Five-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in a Low/Intermediate-Risk Real-world Population

Presenter: Horst Sievert, Brian K. Whisenant, Marco Barbanti

September 23, 2018

Presentation TCT 2018

Low Surgical Risk Aortic Stenosis In The Us: The Patient Really Wants TAVR

Presenter: Vinayak Bapat, Susheel K. Kodali, Philippe Genereux, Martin B. Leon, Scott Lim, Michael J. Mack, Raj Makkar, Patrick T. O'Gara, Michael J. Reardon, Allan Schwartz

September 23, 2018

Presentation TCT 2018

My Crystal Ball - Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis Once the Cycle of Low-Risk Studies is Completed

Presenter: Allan Schwartz, Stephan Windecker, Michael J. Reardon

September 22, 2018

Presentation TCT 2018

The Case for TAVR in Low-Risk Patients: Rationale, Current Data, Clinical Trends, and Updates from the Ongoing Clinical Trials

Presenter: Allan Schwartz, Stephan Windecker, Jeffrey J. Popma

September 22, 2018

Presentation The Structural Heart Disease Summit 2018

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Presenter: Susheel K. Kodali, Michael J. Reardon, Patrick M. McCarthy

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Once the Cycle of Low-Risk Studies is Completed, Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis

Presenter: Allan Schwartz, Stephan Windecker, Michael J. Reardon

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

NOTION 1 - Five-Year FU and Notion 2 - Young & Low-Risk

Presenter: Lars Sondergaard

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

UK All-Comers

Presenter: Neil E. Moat

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Evolut R Low-Risk

Presenter: Jeffrey J. Popma

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Partner 3 Low-Risk

Presenter: Martin B. Leon

June 21, 2018

Presentation EuroPCR 2018

Longevity of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients with Severe Aortic Stenosis and Lower Surgical Risk

Presenter: Lars Sondergaard

May 25, 2018

Presentation EAS 2018

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presenter: Brian A. Ference

May 07, 2018

Presentation CRT 2018

Transcatheter Aortic Valve Replacement for Patients with Severe Aortic Stenosis who are at Low Risk For Mortality: Interim results from the Prospective Multicenter LRT Clinical Trial

Presenter: Ron Waksman

March 04, 2018

Presentation ISET 2018

Best Techniques in 2018 for CAS Performance at Low Risk

Presenter: Chris Metzger

February 04, 2018

Presentation

Efficacy of High-Sensitivity Troponin T in Identifying Very-Low-Risk Patients With Possible ACS

December 14, 2017

Advertisement

Primary Results From the Evolut Low Risk Trial

PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis

Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis

Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Low Risk

TAVR is Here to Stay: What About TAVR in Low-Risk Patients?

OBSERVANT: Five-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in a Low/Intermediate-Risk Real-world Population

Low Surgical Risk Aortic Stenosis In The Us: The Patient Really Wants TAVR

My Crystal Ball - Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis Once the Cycle of Low-Risk Studies is Completed

The Case for TAVR in Low-Risk Patients: Rationale, Current Data, Clinical Trends, and Updates from the Ongoing Clinical Trials

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Once the Cycle of Low-Risk Studies is Completed, Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis

NOTION 1 - Five-Year FU and Notion 2 - Young & Low-Risk

UK All-Comers

Evolut R Low-Risk

Partner 3 Low-Risk

Longevity of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients with Severe Aortic Stenosis and Lower Surgical Risk

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Transcatheter Aortic Valve Replacement for Patients with Severe Aortic Stenosis who are at Low Risk For Mortality: Interim results from the Prospective Multicenter LRT Clinical Trial

Best Techniques in 2018 for CAS Performance at Low Risk

Efficacy of High-Sensitivity Troponin T in Identifying Very-Low-Risk Patients With Possible ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content